Log In
BCIQ
Print this Print this
 

Anti-miR-122, RG-101

  Manage Alerts
Collapse Summary General Information
Company Regulus Therapeutics Inc.
DescriptionGalNAc-conjugated antagonist targeting miR-122
Molecular Target MicroRNA-122 (miR-122)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 or 4 infection in treatment-naïve patients; Treat chronic HCV infection; Treat HCV genotypes 1 and 3 infection in treatment-naïve patients; Treat HCV infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/03/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today